Tyrosine Kinase


Receptor tyrosine kinases bind to extracellular ligands/growth factors, which promotes receptor dimerization and autophosphorylation of receptor tyrosine residues. This triggers a cascade of downstream events through phosphorylation of intracellular proteins that ultimately transduce the extracellular signal to the nucleus, causing changes in gene expression. Receptor tyrosine kinases include EGFR/ErbB, PDGFR, VEGFR, FGFR and MET subfamilies etc. Dysfunctions in tyrosine phosphorylation are linked to oncogenic transformation. In additions, various adaptor and effector proteins couple to carboxy-terminal of an active kinase. For instance, binding of the GRB2 adaptor protein activates EGFR and MAPK/ERK signaling.
Non-receptor tyrosine kinases involve many well-defined proteins (e.g. the Src family kinases, c-Abl, and Jak kinases) and other kinases which regulates cell growth and differentiation. For example, Src family kinases are curial for activating and inhibitory pathways in the innate immune response.
-
B5859 EntrectinibTarget: Trk Receptors|ALK|ROS1Summary: Orally active inhibitor of ALK kinase -
B5864 Fruquintinib(HMPL-013)Target: VEGFRSummary: Potent and selective inhibitor of VEGFR 1, 2, 3 -
B5889 EGF8162 CitationTarget: EGFRSummary: Novel covalent inhibitor of mutant-selective EGFR -
B5899 CL-387785 (EKI-785)Summary: Irreversible inhibiter of EGFR -
B5953 Dovitinib (TKI258) LactateTarget: CSF-1R|FLT3|VEGFR|PDGFR|c-Kit|FGFRSummary: Oral tyrosine kinase inhibitor (TKI) against FGFR1–3, VEGFR1–3, and platelet-derived growth factor receptor (PDGFR). -
B6006 NPS-1034Summary: MET inhibitor -
B6033 GNF-7Summary: Type II Bcr-Abl inhibitor -
B6054 EAI045Summary: Inhibitor of L858R/T790M EGFR mutants -
B1299 1-NM-PP1Target: Cyclin-Dependent Kinases|Bcr-Abl|Src|Ca2 /calmodulin-dependent protein kinases (CaMKs)|c-FynSummary: Pp60c-src inhibitor -
B1103 Mutant EGFR inhibitorSummary: Selective Mutated EGFR inhibitor
